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Backgroud: Previous pirfenidone trials have only involved patients with mild-to-moderate idio-
pathic pulmonary fibrosis (IPF). The aim of this study was to investigate the safety and efficacy
of pirfenidone in patients with mild-to-severe IPF in clinical practice.
Methods: The clinical records of 76 patients who were diagnosed with IPF and received pirfe-
nidone were reviewed.
Results: The most frequent adverse event was anorexia, although the grade of anorexia in
most patients was mild. Dose reduction of pirfenidone improved anorexia in 84% affected pa-
tients, which resulted in a high medication compliance rate. The mean forced vital capacity
(FVC) at the initiation of pirfenidone therapy in this study was approximately 10% lower than
that in previous clinical trials. The mean change in FVC during the 6-month period prior to the
therapy initiation was 188 mL, which improved to 19 mL during the 6-month period after
therapy. Significant attenuation in percentage predicted diffusion capacity of the lung for car-
bon monoxide decline was also achieved after pirfenidone therapy initiation. The efficacy of
pirfenidone in attenuating the degree of FVC decline was higher in the group with FVC decline
of 150 mL during the 6-month period prior to therapy initiation. The levels of serum markers,
such as KL-6 and SP-D, were also lowered by the therapy.
Conclusions: These results showed that pirfenidone was well-tolerated and had beneficial ef-
fects in patients with mild-to-severe and/or progressive IPF. The degree of disease progression
prior to the initiation of pirfenidone therapy had an impact on the response to the therapy.
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co.jp (R. Okuda), hagiwara@kanagawa-junko.jp (E. Hagiwara), baba@kanagawa-junko.jp (T. Baba),
mura), t-kato@kanagawa-junko.jp (T. Kato), ogura@kanagawa-junko.jp (T. Ogura).
3 Elsevier Ltd. All rights reserved.
3.06.011
1432 R. Okuda et al.Introduction weeks after completion of the therapy) were assessed ac-
cording to the system organ class and grading specified inIdiopathic pulmonary fibrosis (IPF) is an entity of interstitial
pneumonia that has an unfavorable prognosis; approxi-
mately 50% patients die within 2e5 years from diagnosis
[1]. No effective drugs were available for treating IPF until
2008, when a phase III trial conducted in Japan demon-
strated that pirfenidone attenuated the decline in vital
capacity (VC) and prolonged the progression-free survival in
patients with mild-to-moderate IPF [2]. In the CAPACITY 2
study conducted in 13 countries, pirfenidone was shown to
significantly attenuate the decline in the percent change of
forced vital capacity (FVC) in patients with mild-to-
moderate IPF [3]. Pirfenidone was approved for the treat-
ment of IPF in Japan in 2008 and for the treatment of adult
patients with mild-to-moderate IPF in the EU in 2011.
Although the statement issued by the American Thoracic
Society, the European Respiratory Society, the Japanese
Respiratory Society and the Latin American Thoracic Asso-
ciation in 2011 [4] gave a weak recommendation on the use
of pirfenidone for treating IPF, pirfenidone is one of the
drugs expected to be a useful therapeutic agent for IPF
because clinical trials with the three-drug regimen of
prednisolone þ azathioprine þ N-acetylcysteine and those
with warfarin have shown negative results [5].
The study cohorts in previous pirfenidone trials only
involved patients with mild-to-moderate IPF; therefore the
efficacy of pirfenidone in patients with severe IPF remains
unclear. However, in Japan it is not uncommon to treat
severe IPF patients with pirfenidone in the clinical setting.
The present study attempted to assess the safety and ef-
ficacy of pirfenidone therapy in IPF patients, including
those with severe disease.
Methods
Subjects
The study was designed and conducted at a single institu-
tion in Yokohama, Japan. The clinical records of patients
who were diagnosed with IPF and who were administered
pirfenidone between December 1, 2008 and March 31, 2011
were retrospectively investigated in this study. The diag-
nosis of IPF was established in every case in accordance
with the American Thoracic Society, the European Respi-
ratory Society, the Japanese Respiratory Society and the
Latin American Thoracic Association statement issued in
2011 [4]. The pirfenidone dose was escalated over 28 days
to the full dose of 1800 mg per day. All patients were
included in the safety analysis; only those who underwent
all three respiratory function tests 6 months before, at the
initiation of pirfenidone therapy and 6 months after were
included in the efficacy evaluation set. This study was
approved by institutional review board of Kanagawa Car-
diovascular and Respiratory Center.
Data analysis
For evaluation of safety, adverse events that occurred from
the initiation to 13 months of pirfenidone therapy (or until 4the Common Terminology Criteria for Adverse Events ver.
4.0 by reviewing medical records. The time of onset was
counted from the initiation of treatment. Efficacy evalua-
tion was performed on the basis of the degree of FVC
decline during the 6-month period after initiation of pir-
fenidone therapy as an assessment parameter, which was
similar to the CAPACITY 1 and 2 studies. Other assessment
parameters included the changes in percentage predicted
diffusion capacity of the lung for carbon monoxide (%DLco),
serum levels of interstitial pneumonia markers (KL-6 and
SP-D), arterial oxygen tension, and the distance in the 6-
min walk test (6MWT). The frequency of acute exacerba-
tions of IPF during the 1-year period after the initiation of
pirfenidone therapy was also evaluated. Acute exacerba-
tion of IPF was diagnosed as per the Japanese guideline on
the basis of the presence of the following criteria:
increased severity of dyspnea, presence of honeycomb lung
features and newly-appearing ground-glass opacities and
infiltrates on high-resolution CT and a decrease in arterial
oxygen tension by 10 mmHg, after exclusion of other
disorders such as overt infection and cardiac failure. Dis-
ease severity of IPF was determined as per the Japanese
guideline. Patients having PaO2 80 Torr were classified as
stage I, 70 Torr and <80 Torr as stage II, 60 Torr and
<70 Torr as stage III, and <60 Torr as stage IV. For patients
with stage II or more, if the SpO2 during the 6MWT was less
than 90%, the disease severity should be increased by one
stage. The patients were categorized by the disease
severity using criteria of the USA as defined by the features
of baseline %VC (<65%), SpO2 on 6MWT (88%), and %DLco
(<50%); the patients had no feature were stratified in mild,
one feature in moderate, and two or more in severe
disease.
Statistical analysis
Data are presented as mean  standard deviation, unless
otherwise stated. An unpaired t-test, a paired t-test or Chi-
square test was used to compare numerical variables, and
p-values <0.05 were considered statistically significance.
Statistical analyses were carried out using GraphPad Prism
5J (MDF CO., Ltd.).
Results
Patient background characteristics
The background characteristics of the 76 patients with IPF
are summarized in Table 1. The patients comprised 60
males and 16 females, with a mean age of 70.5 years.
Surgical lung biopsy was performed in 36 cases (47%). Ac-
cording to the severity grading criteria currently used in
Japan, the severity of IPF was classified as grade I in 20
patients, grade II in 11 patients, grade III in 15 patients,
grade IV in 27 patients and unmeasurable because of
missing test data in three patients. The mean values of the
respiratory function parameters in the study population
were as follows: FVC, 2.04 L; %FVC, 65.3% and %DLco,
Table 1 Baseline clinical characteristics and laboratory
data.
Characteristics
Subjects 76
Male 60
Female 16
Age (yrs) 70.5  8.3
Smoking history
Never smoker 16
Ex- and current smokers 60
Brinkman index 849  637
Surgical lung biopsy
Yes 36
No 40
IPF ATS/ERS statement
IPF 66
Probable IPF 2
Possible IPF 8
Treatment period (day) 282  113
Prior treatment received
No 59
Yes 17
Steroids only 7
Steroids þ immunosuppressant 10
Immunosuppressant only 0
Average dose of prednisolone (mg/day) 7.8  2.5
Combined treatment received with pirfenidone
No 44
Yes 32
Steroids only 19
Steroids þ immunosuppressant 13
Immunosuppressant only 0
Average dose of prednisolone (mg/day) 9.6  3.4
Disease severity
(criteria of the Japanese Respiratory Society)
I/II/III/IV/unmeasurable
(criteria of the USA)
20/11/15/27/3
Mild/moderate/severe/unmeasurable 11/38/11/17
Blood tests
KL-6 (U/ml) 1428  1129
SP-D (ng/ml) 323  280
PaO2 (Torr) 76.0  11.9
Pulmonary function
VC (L) 2.05  0.61
VC % pred 66.5  15.8
FVC (L) 2.04  0.61
FVC % pred 65.3  16.1
FEV1 (L) 1.67  0.48
DLco % pred 55.9  17.8
6MWT
Distance (m) 313  105
Lowest SpO2 (%) 86.0  5.5
Data are presented as n, n(%) or mean  standard deviation,
unless otherwise stated. VC: vital capacity; %pred: % predicted;
FVC: forced vital capacity; DLco: diffusion capacity of the lung
for carbon monoxide; KL-6: Kerb von den Lungen-6; SP-D: sur-
factant protein D; PaO2: arterial oxygen tension; 6MWT: 6-min
walk test; SpO2: oxygen saturation measured by pulse oxime-
try. Brinkman index: daily number of cigarettes  years.
Safety and efficacy of pirfenidone 143355.9%; thus, the patients had restrictive ventilatory defect
and impaired diffusing capacity. The mean levels of both
interstitial pneumonia markers were elevated: KL-6,
1428 U/mL (reference range:152e400 U/mL) and SP-D,
323 ng/mL (reference range : 0e109.9 ng/mL).
Safety
Pirfenidone therapy was discontinued in 34.2% patients; of
these, 18.4% patients discontinued therapy because of the
occurrence of adverse events. Another major reason for
discontinuation was poor general condition that made oral
intake of the medication difficult.
Table 2 shows the incidence of adverse events and their
time of occurrence. Anorexia occurred at an incidence as
high as 42%; however, it was mild (grade 2) in almost all
cases. Anorexia improved following dose reduction of pir-
fenidone in 84% affected patients, which resulted in a high
medication compliance rate. The mean time of anorexia
onset was approximately 90 days. There was no correlation
between anorexia and age of IPF onset (p Z 0.273) or
disease severity; there was also no correlation between
anorexia and use of steroid and/or immunosuppressive
drugs (Table 3).
In contrast, the incidence of photosensitivity was 18%,
which was lower than that reported in a phase III trial in
Japan (Table 2). The incidences of other adverse events
were generally comparable with those reported from a
phase III trial conducted in Japan. All the reported adverse
events were reversible and left no sequelae.
Effects on the assessment parameters
The mean change  standard error in FVC from baseline
value during 6 months prior to the pirfenidone therapy
was188 34 mL, which was a significant decrease from theTable 2 Summary of adverse events.
Grade
Total 1 2 3 4e5 Onset of events
Adverse events 64 (84.2) (days)
Photosensitivity 14 (18.4) 9 5 0 0 116  63
Anorexia 32 (42.1) 23 7 2 0 96  97
Nausea 9 (11.8) 7 2 0 0 145  135
Gastric distress 9 (11.8) 9 0 0 0 83  95
Fatigue 11 (14.5) 6 5 0 0 114  107
Drowsiness 5 (6.6) 5 0 0 0 80  94
Rash 5 (6.6) 5 0 0 0 134  75
Hepatic dysfunction
g-GTP elevation 17 (22.4) 13 4 0 0 128  83
AST elevation 13 (17.1) 12 0 1 0 93  80
ALT elevation 14 (18.4) 13 0 1 0 119  96
Others 4 (5.3) 4 0 0 0
Data are presented as n, n(%) or mean  standard deviation.
The time of onset was counted from the initiation of treatment.
AST: aspartate aminotransferase; ALT: alanine aminotrans-
ferase; g-GTP: g－glutamyl transpeptidase. Others included dry
eye, dry month, vomiting and allergic reaction.
Table 3 Correlation between anorexia and disease
severity or use of drugs.
Criteria of the Japanese Respiratory Society
Disease severity Anorexia (+) Anorexia ()
I 7 13
II 4 7
III 7 8
IV 14 13
Criteria of the USA
Disease severity Anorexia (+) Anorexia ()
I 4 7
II 17 21
III 5 6
Use of drugs
Anorexia (+) Anorexia ()
Pirfenidone only 20 24
Combined treatment 12 20
1)p = 0.875, 2)p = 0.651, 3)p = 0.488. Data are presented as n.
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Figure 1 Change from 6months before therapy in forced vital
capacity (FVC). The change in FVC from the baseline value
(6months before initiation of pirfenidone therapy) was188mL
at initiation of therapy and 207 mL after 6 months of therapy.
Paired t-test was used. Data are presented as mean  standard
error. ): p-value <0.05.
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Figure 2 Change in percentage predicted diffusion capacity
of the lung for carbon monoxide (%DLco). Change in %DLco
from the baseline value (6 months before initiation of pirfe-
nidone therapy) was 8.5% at initiation of therapy and 7.9%
after 6 months of pirfenidone therapy. Paired t-test was used.
Data are presented as mean  standard error. ＊: p-value
<0.05.
1434 R. Okuda et al.baseline (P< 0.001). Themeanchange standarderror in FVC
from baseline value during 12 months prior to the pirfenidone
therapy was 207  32 mL. Significant attenuation in degree
of FVC decline was observed after 6 months of pirfenidone
therapy (Fig. 1).
The mean change  standard error in %DLco from
baseline value during 6 months prior to the pirfenidone
therapy was 8.5  3.0%, which was a significant decrease
from the baseline (PZ 0.01). The mean change  standard
error in %DLco from baseline value during 12 months prior
to the pirfenidone therapy was 7.9  3.4%, which meant
0.6% increase from initiation (Fig. 2). Significant attenua-
tion in the degree of decline in %DLco was achieved after
pirfenidone therapy initiation.
In an attempt to account for the influence of concomi-
tantly administered drugs, the observed changes in FVC
were compared between a group that received pirfenidone
alone and one that received concomitant corticosteroid
and/or immunosuppressant therapy with pirfenidone. The
comparison revealed no significant intergroup differences
in the effects of pirfenidone.
Analysis of the data stratified by %FVC at the initiation of
pirfenidone therapy revealed that pirfenidone tended to
attenuate the degree of decline in FVC, particularly in the
subgroup of patients with %FVC <60% (Table 4). When the
patients were classified into two groups according to the
degree of decline in FVC (150 mL vs. <150 mL) during the
6-month period before therapy initiation, pirfenidone
showed greater efficacy in attenuating FVC decline in the
150-mL group than in the <150-mL group (Table 4). It
divided by 150 mL so that two groups might become the
almost same number of patients. The reported mean
decline in FVC during 6-month period was 75e100 mL in
placebo groups [2]. When the patients were classified into
two groups according to the degree of decline in FVC
(100 mL vs. <100 mL) during the 6-month period beforetherapy initiation, pirfenidone showed greater efficacy in
attenuating FVC decline in the 100-mL group than in the
<100-mL group.
There were no other factors, including gender, smoking,
age, and PaO2 that affected the efficacy of pirfenidone
(Table 5).
The absolute serum level of KL-6 increased significantly
during the 6-month period before treatment (P Z 0.016).
The absolute serum levels of KL-6 (P Z 0.016) and SP-D
(P Z 0.039) decreased significantly after therapy initia-
tion (Fig. 3), whereas no significant improvement was noted
in the minimum oxygen saturation measured by pulse ox-
imetry or the distance in the 6MWT (Table 6).
Acute exacerbation of IPF occurred in four of the 76
patients (5.3%), two patients (50%) died because of acute
exacerbation.
Table 4 FVC decline in subpopulations characterized by %FVC and by change in FVC before therapy.
%FVC at initiation
of therapy
n Mean change in
FVC for 6 months
before therapy (ml)
Mean change in FVC for 6
months after therapy (ml)
p-Value
%FVC 80 4 60  96 80  69 0.840
80> %FVC 70 11 130  58 20  70 0.282
70> %FVC 60 10 210  44 60  63 0.156
60> %FVC 11 280  72 80  55 0.074
Decline in FVC for 6
months before therapy
n Mean change in FVC
for 6 months before
therapy (ml)
Mean change in FVC for 6
months after therapy (ml)
p-Value
150 ml 16 350  48 30  58 <0.001
<150 mL 20 60  20 100  31 0.274
Paired t-test was performed. Values are given as mean  standard error.
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This study demonstrated that pirfenidone was well-
tolerated and significantly attenuated the degree of FVC
decline in patients with mild-to-severe IPF, especially in
those with progressive disease in clinical practice.
The rate of discontinuation of the drug because of
adverse events in this study (18.4%) was essentially similar
to those in a phase III clinical trial in Japan (19%) and the
CAPACITY 1 and 2 studies (14.8%). The incidence of
anorexia in the present study was relatively higher than
that in patients treated in the Japanese clinical trial (23%;
n Z 265) and in the CAPACITY 1 and 2 studies (11%).
However, the incidence of nausea in the CAPACITY 1 and 2
studies was as high as 36%, and the incidence of all
gastrointestinal symptoms was almost comparable between
the present study and the CAPACITY 1 and 2 studies. Often,
in this study, the gastrointestinal symptoms improved
following dose reduction of pirfenidone, and it has been
reported that the effect of the drug in attenuating the
degree of decline in VC was evident even at a low-dose
level of 1200 mg/day [2]. Continuation of pirfenidone
therapy by dose reduction rather than cessation of pirfe-
nidone therapy should be considered. The mean time ofTable 5 Effects of the five variables.
Parameters p-Value
Male vs. female 0.801
Smoker vs. never-smoker 0.137
Age: <70 vs. 70 0.849
DFVC: <150 mL vs. 150 mL >0.001
PaO2: <70 Torr vs. 70 Torr 0.340
The difference of FVC decline during the 6-month period before
the initiation of pirfenidone therapy and during the 6-month
period after the initiation of pirfenidone therapy, was used as
the efficacy parameter. The effects of the five variables
(gender, smoking, age, the FVC decline during the 6-month
period before the initiation of pirfenidone therapy and PaO2)
were evaluated with ManneWhitney’s U-test.anorexia onset in this study was almost identical to that
reported in the Japanese clinical trials.
In this study, the incidence of photosensitivity was lower
compared than the 51% rate reported in the Japanese
clinical trials. The lower incidence of photosensitivity was
possibly as a result of our effort in improving the frequency
of use of sunscreens and long-sleeved shirt- and hat-
wearing, based on the results of the clinical trials. It was
thought that the photosensitivity could be suppressed if sun
exposure was avoided. Other adverse events were also
mild, indicating general satisfactory safety and tolerability
of the drug.
Currently, it is extremely difficult to use death as a
primary endpoint for evaluation of the therapeutic re-
sponses of IPF patients in clinical trials and clinical studies,
because of the low prevalence of IPF. It has been reported
that the degrees of change in VC or FVC over a 6e12-month
period may serve as potent predictors of death in the
following year [6e8], and changes in VC or FVC currently
represent highly reliable endpoints in the treatment of IPF.50
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Figure 3 Paired t-test was performed for the cases which
conducted the blood tests all 3 times (43 cases in KL-6, 41 cases
in SP-D). The absolute serum levels of KL-6 and SP-D were
shown and improved significantly after initiation of pirfenidone
therapy. Data are presented as mean  standard error. KL-6:
Kerb von den Lungen-6; SP-D: surfactant protein D. ＊: p-
value <0.05.
Table 6 Comparison of 6-min walk test results.
6MWT
n Initiation of
therapy
n 6 months after
therapy
p-Value
Mini SpO2 (%) 33 86  1 20 88  1 0.399
Distance (m) 29 342  21 13 383  32 0.143
6MWT: 6-min walk test; SpO2: oxygen saturation measured by
pulse oximetry. Data are presented as mean  standard error.
1436 R. Okuda et al.The present study population included a considerable
proportion of patients with severe disease, as indicated by
the mean baseline FVC that was approximately 10% lower
than that in the patient groups of the aforementioned
clinical trials reported in Japan and other countries.
Although there are few reports documenting the effec-
tiveness of pirfenidone in cases of severe IPF [9,10], the
results of our present study suggest that pirfenidone would
also be effective in patients with severe IPF. One of the
reasons why there were more than a few cases of severe IPF
at the start of pirfenidone therapy in this study is that
under the present circumstances in Japan, medical ex-
penses are paid by the public for patients with severe IPF,
who thus are in a better situation to receive expensive
pirfenidone therapy.
Compared with a decline in FVC by approximately
0.15e0.2 L over a 1-year period in the placebo group re-
ported from a clinical trial conducted on mild-to-moderate
disease cases, FVC decreased by as much as 0.19 L during
the 6-month period before initiation of pirfenidone therapy
in the present study. One reason for this trend may be
attributable to the higher likeliness of starting pirfenidone
therapy in patients with symptomatic exacerbation or
worsening of their laboratory values.
The effect of the therapy was more pronounced in the
group with a greater decline of FVC during the 6-month
period prior to the initiation of therapy in this study.
Therefore, it was inferred that the pre-therapy rate of
disease progression also influenced the efficacy of pirfeni-
done. There might be relatively moderate-to-severe com-
ponents of interstitial inflammation and fibrosis of lung in
the group with a greater decline of FVC during the 6-month
period prior to the initiation of therapy; pirfenidone com-
pound with antifibrotic and anti-inflammatory effects might
be more effective in moderate-to-severe interstitial
inflammation and fibrosis.
Furthermore, it has been documented from a stratified
analysis of the data from a phase III clinical trial that pir-
fenidone exerted greater efficacy in patients with a base-
line %VC of 70% and a baseline minimum oxygen
saturation measured by pulse oximetry of <90% in the
6MWT [11]. Pirfenidone was effective even in patients with
baseline values of <60% in the present study. It would be
reasonable to infer that in the group with a %FVC of <60% in
this study, the patients were more responsive to the effect
of pirfenidone because of the greater degree of FVC decline
during the 6-month pre-therapy period in this group.
There have been sporadic reports of improvement in the
serum levels of interstitial pneumonia markers following
treatment with pirfenidone, and statistically significantimprovements were noted in this study. One study
demonstrated that KL-6 served as a predictor of the disease
activity in cases of IPF [12], and these interstitial pneu-
monia markers may serve as useful indicators of the ther-
apeutic responses, because their assay is procedurally
simple, unlike respiratory function testing. Although this
study did not examine the change in radiological images,
computed tomography has been reported to be useful to
assess the efficacy of pirfenidone [13].
Acute exacerbation of IPF reportedly occurs at an
approximate yearly incidence of 5%e15% [14,15] and is
associated with a mortality rate of 60% [16]. The incidence
of acute exacerbation in this study was approximately 5%,
similar to that reported for the placebo group and the
pirfenidone-treated group in the phase III clinical trial;
therefore, no evidence was found regarding a suppressive
effect of pirfenidone on the development of acute exac-
erbations of IPF.
This investigation had some limitations. The efficacy of
pirfenidone was retrospectively examined, and it is possible
that the number of patients in this study was not sufficient
for reliable evaluation. There were a substantial number of
patients who did not undergo respiratory function testing in
both before therapy and on therapy and were therefore
excluded from the efficacy evaluation. The possibility of
bias related to the selection of patients with mild disease
for 6MWT in this study cannot be ruled out because the data
were compared solely among patients who underwent
6MWT in room air.
Furthermore, 42% patients were concomitantly receiving
corticosteroids or immunosuppressants, and there was no
significant difference in the therapeutic response between
the pirfenidone monotherapy group and the combined drug
regimen group; however, the possibility that the concomi-
tant medication may have affected the respiratory function
parameters and/or the risk of occurrence of adverse re-
actions remains to be explored.
In conclusion, our results showed that pirfenidone was
well-tolerated and dose reduction of pirfenidone resulted
in a high medication compliance rate. Pirfenidone proved
effective in attenuating the degree of FVC decline in clin-
ical settings. Baseline decline of FVC had been confirmed in
the patients subjected to the efficacy evaluation in this
study, and pirfenidone was more beneficial in patients with
a greater FVC decline during the 6-month period before
initiation of the therapy.Conflict of interest statement
Ryo Okuda has no conflicts of interest. Eri Hagiwara has no
conflicts of interest. Tomohisa Baba has no conflicts of in-
terest. Hideya Kitamura has no conflicts of interest. Ter-
ufumi Kato has no conflicts of interest. Takashi Ogura has
participated as a lecturer and speaker in scientific meetings
and courses under the sponsorship of Shionogi & CO., Ltd.Acknowledgments
The authors would like to thank Enago (www.enago.jp) for
the professional English language review.
Safety and efficacy of pirfenidone 1437References
[1] American Thoracic Society/European Respiratory Society. ATS
statement. Idiopathic pulmonary fibrosis: diagnosis and
treatment. International consensus statement. Am J Crit Care
Med 2000;161:646e64.
[2] Taniguchi H, Ebina M, Kondoh Y, Ogura T, Azuma A, Suga M,
et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J
2010;35:821e9.
[3] Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK,
Kardatzke D, et al. Pirfenidone in patients with idiopathic
pulmonary fibrosis (CAPACITY): two randomized trials. Lancet
2011;377:1760e9.
[4] Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK,
et al. ATS/ERS/JRS/ALAT committee on idiopathic pulmonary
fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic
pulmonary fibrosis: evidence-based guidelines for diagnosis and
management. Am J Respir Crit Care Med 2011;183:788e824.
[5] Idiopathic Pulmonary Fibrosis Clinical Research Network,
Raghu G, Anstrom KJ, King Jr TE, Lasky JA, Martinez FJ.
Prednisone, azathioprine, and N-acetylsysteine for pulmonary
fibrosis. N Engl J Med 2012;366:1968e77.
[6] Taniguchi H, Kondoh Y, Ebina M, Azuma A, Ogura T, Taguchi Y,
et al. The clinical significance of 5% change in vital capacity in
patients with idiopathic pulmonary fibrosis: extended analysis
of the pirfenidone trial. Respir Res 2011;12:93.
[7] Collard HR, King Jr TE, Bartelson BB, Vourlekis JS, Schwarz MI,
Brown KK. Changes in clinical and physiologic variables predict
survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care
Med 2003;168:538e42.
[8] Zappala CJ, Latsi PI, Nicholson AG, Colby TV, Cramer D,
Renzoni EA, et al. Marginal decline in forced vital capacity isassociated with a poor outcome in idiopathic pulmonary
fibrosis. Eur Respir J 2010;35:830e5.
[9] Raghu G, Johnson C, Lockhart D, Mageto Y. Treatment of
idiopathic pulmonary fibrosis with a new antifibrotic
agent, pirfenidone. Am J Respir Crit Care Med 1999;159:
1061e9.
[10] Nagai S, Hamada K, Shigematsu M, Taniyama M, Yamauchi S,
Izumi T. Open-label compassionate use one year-treatment
with pirfenidone to patients with chronic pulmonary fibrosis.
Intern Med 2002;41:1118e23.
[11] Azuma A, Taguchi Y, Ogura T, Ebina M, Taniguchi H,
Kondoh Y, et al. Exploratory analysis of a phase III trial of
pirfenidone identifies a subpopulation of patients with
idiopathic pulmonary fibrosis as benefiting from treatment.
Respir Res 2011;12:143.
[12] Yokoyama A, Kohno N, Hamada H, Sakatani M, Ueda E,
Kondo K, et al. Circulating KL-6 predicts the outcome of
rapidly progressive idiopathic pulmonary fibrosis. Am J Respir
Crit Care Med 1998;158:1680e4.
[13] Iwasawa T, Ogura T, Sakai F, Kanauchi T, Komagata T, Baba T,
et al. CT analysis of the effect of pirfenidone in patients with
idiopathic pulmonary fibrosis. Eur J Radiol 2012 [in press].
[14] Azuma A, Nukiwa T, Tsuboi E, Suga M, Abe S, Nakata K, et al.
Double-blind, placebo-controlled trial of pirfenidone in pa-
tients with idiopathic pulmonary fibrosis. Am J Respir Crit
Care Med 2005;35:821e9.
[15] Song JW, Hong SB, Lim CM, Koh Y, Kim DS. Acute exacerbation
of idiopathic pulmonary fibrosis: incidence, risk factors and
outcome. Eur Respir J 2011;37:356e63.
[16] Agarwal R, Jindal SK. Acute exacerbation of idiopathic pul-
monary fibrosis: a systematic review. Eur J Intern Med 2008;
19:227e35.
